Gene editing reawakens embryonic haemoglobin in alpha thalassaemia models
Researchers reactivated an embryonic globin gene normally silenced after early development, offering a preclinical approach to severe alpha thalassaemia. Editing regulatory DNA increased zeta-globin production in patient-derived blood-cell precursors and improved survival of mouse embryos. The strategy targets an alternative chain for haemoglobin rather than restoring the missing alpha-globin genes.
Science··Night
An embryonic gene offers a substitute chain
Gene editing reactivated embryonic zeta-globin in blood-cell precursors obtained from patients with severe alpha thalassaemia and improved survival in a mouse disease model. The peer-reviewed investigation targets a gene normally silenced after early development. Its preclinical findings concern restoring production of an alpha-like haemoglobin component, with experiments in cells and embryos rather than a treatment administered to patients.[1], [2]
Adult haemoglobin contains two alpha and two beta chains. A shortage of alpha-globin underlies alpha thalassaemia; severe forms can require repeated transfusions or stem-cell transplantation. Zeta-globin is an embryonic alpha-like chain whose production normally ends around weeks 6–7 of human gestation. In the common Southeast Asian deletion, both alpha-globin genes are lost while the zeta gene and its enhancers remain.[1]
Two regulatory sites keep zeta-globin silent
The researchers localized silencing activity to a 4.4-kilobase DNA region and identified two repressive elements in the gene’s promoter, the region controlling transcription. Binding sites for BCL11A and LRF were disrupted separately and together. The combined changes increased zeta-globin expression. A screen in mouse blood-cell precursors used 47 guide RNAs spread across 700 bases; subsequent measurements tracked editing, cell viability and globin production.[1]
Edited embryos survive further into development
Mouse embryos modelling Hb Bart’s hydrops fetalis syndrome normally die before birth. With the promoter changes, embryos reached the late developmental stage E17.5 and had haemoglobin containing zeta and beta chains. Blood cells from patients with haemoglobin H disease or Hb Bart’s syndrome had higher zeta-globin expression after editing than the mouse model. These experiments investigated a retained alternative gene rather than repairing the deleted alpha genes.[1]
Haemoglobin assembled from zeta and beta chains has oxygen-binding properties and chain interactions that differ from normal adult haemoglobin. Those physiological properties need assessment before clinical application. The embryo result does not establish recovery after birth or a lasting benefit in adults. Single-site and double-site edits were also generated using different methods, which constrains direct comparisons between those experimental cell groups.[1]
